Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2022 and recent corporate updates. “Mirati continues to advance the development of a broad portfolio of…

Click here to view original post